title: Significance and suppression of redundant IL17 responses in acute allograft rejection by bioinformatics based drug repositioning of fenofibrate.
abstract: Despite advanced immunosuppression, redundancy in the molecular diversity of acute rejection (AR) often results in incomplete resolution of the injury response. We present a bioinformatics based approach for identification of these redundant molecular pathways in AR and a drug repositioning approach to suppress these using FDA approved drugs currently available for non-transplant indications. Two independent microarray data-sets from human renal allograft biopsies (n = 101) from patients on majorly Th1/IFN-y immune response targeted immunosuppression, with and without AR, were profiled. Using gene-set analysis across 3305 biological pathways, significant enrichment was found for the IL17 pathway in AR in both data-sets. Recent evidence suggests IL17 pathway as an important escape mechanism when Th1/IFN-y mediated responses are suppressed. As current immunosuppressions do not specifically target the IL17 axis, 7200 molecular compounds were interrogated for FDA approved drugs with specific inhibition of this axis. A combined IL17/IFN-y suppressive role was predicted for the antilipidemic drug Fenofibrate. To assess the immunregulatory action of Fenofibrate, we conducted in-vitro treatment of anti-CD3/CD28 stimulated human peripheral blood cells (PBMC), and, as predicted, Fenofibrate reduced IL17 and IFN-γ gene expression in stimulated PMBC. In-vivo Fenofibrate treatment of an experimental rodent model of cardiac AR reduced infiltration of total leukocytes, reduced expression of IL17/IFN-y and their pathway related genes in allografts and recipients' spleens, and extended graft survival by 21 days (p<0.007). In conclusion, this study provides important proof of concept that meta-analyses of genomic data and drug databases can provide new insights into the redundancy of the rejection response and presents an economic methodology to reposition FDA approved drugs in organ transplantation.
authors: Transplant Research Program Sutter Health Care, California Pacific Medical Center, San Francisco, California, USA.
authors: Silke
authors: S
authors: Roedder
authors: Naoyuki
authors: N
authors: Kimura
authors: Homare
authors: H
authors: Okamura
authors: Szu-Chuan
authors: SC
authors: Hsieh
authors: Yongquan
authors: Y
authors: Gong
authors: Minnie M
authors: MM
authors: Sarwal
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D002648:Child; D002675:Child, Preschool; D019295:Computational Biology; D005260:Female; D011345:Fenofibrate / Q000008:administration & dosage; D015870:Gene Expression / Q000187:drug effects; D006084:Graft Rejection / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D016027:Heart Transplantation / Q000379:methods; D006801:Humans; D007165:Immunosuppression Therapy; D007371:Interferon-gamma / Q000378:metabolism; D020381:Interleukin-17 / Q000276:immunology / Q000378:metabolism*; D016030:Kidney Transplantation / Q000276:immunology* / Q000379:methods; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000276:immunology; D008297:Male; D051379:Mice; D046888:Tissue Array Analysis; D014184:Transplantation, Homologous; D055815:Young Adult
chemical_list: D020381:Interleukin-17; D007371:Interferon-gamma; D011345:Fenofibrate